Jeffrey B. Steinberg

Alpha-Beta Technology, Inc. engages in the discovery, development and commercialization of novel carbohydrate-based products for the prevention and treatment of infectious disease. It develops a novel class of immune modulation pharmaceutical products composed of complex carbohydrates and is discovering and developing new anti-fungal diagnostics and drugs. In addition, Alpha-Beta has developed a rapid in vitro diagnostic to detect and monitor systemic fungal infections and has an anti-fungal research program to discover direct inhibitors of fungal cell wall synthesis. It is in the development stage and is devoting substantially all of its efforts toward product research and development, raising capital, marketing products under development, clinical trials and manufacturing. The Company was founded on March 2, 1988 and is headquartered in Worcester, MA.

Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD.

LeukoSite, Inc. develops drugs for treatment of cancer and inflammatory diseases. It produces drugs to block autoimmune and viral diseases associated with malfunctioning leukocytes or white blood cells. The company was founded in 1992 and is located in Cambridge, MA.

FoldRx Pharmaceuticals, Inc. provides drug discovery and clinical development services. It develops and discovers products focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding. The company was founded by Jeffery W. Kelly and Susan L. Lindquist in 2003 and is headquartered in Cambridge, MA.

Adheron Therapeutics, Inc. discovers and develops therapeutic drugs. The firm offers Cadherin-11 antagonists for the treatment of rheumatoid arthritis and fibrotic diseases including pulmonary fibrosis and skin fibrosis. The company was founded by David Lee, Michael B. Brenner, and David L. Castaldi in 2006 and is headquartered in Berkeley, CA.

Mosaic Biosciences, Inc. provides commercial research and development services. It conducts research on synthetic materials that support native tissue regeneration. The firm's solutions are designed for application in wound healing, bone regeneration, cartilage repair, stem cell therapy, and dermal fillers. The company was founded by Martin Stanton, Chris Bowman, Kristi S. Anseth and Peter Mariner in 2009 and is headquartered in Boulder, CO.

Layerbio, Inc. develops bio erodible sustained-release technology for use in standard intraocular lens in cataract surgery. The private company is based in Lexington, MA. The company was founded in 2013 by Kenneth J. Mandell, Paula Hammond. Kenneth J. Mandell has been the CEO since 2013.

HealthCare Ventures LLC (HealthCare Ventures) is a venture capital firm founded in 1985 by Harold R. Werner. The firm is headquartered in Cambridge, Massachusetts.

Part of Amphastar Pharmaceuticals, Inc., Armstrong Pharmaceuticals, Inc. is a company that manufactures aerosol pharmaceutical products. The company is based in New Canaan, CT.

Part of Sanofi, BioSurface Technology, Inc. is a commercial biotechnical research company. The company is based in Cambridge, MA. The company was founded by David L. Castaldi, Ben R. Bronstein. BioSurface Technology was acquired by Genzyme Corp., part of Sanofi from April 08, 2011 on December 16, 1994.

Upstate Group LLC develops cell signaling products, technology platforms and services. It provides researchers at pharmaceutical and biotechnology companies, universities and government agencies with advanced tools to accelerate life science research and drug discovery. Upstate Group is a subsidiary of Serologicals Corp. The company was founded in 1988 and is headquartered in Charlottesville, VA.

Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA.

Arresto Biosciences, Inc. is a biotech company that develops medicines to treat cancer and fibrotic diseases by targeting extracellular matrix proteins. The company was founded by Amato Giaccia, Michael T. Longaker and Geoffrey C. Gurtner in 2007 and is headquartered in Palo Alto, California.

Cleveland HeartLab, Inc. operates as a holding and clinical reference laboratory company. It focuses on novel molecular biomarker technologies and the creation of proprietary diagnostic tests. The company was founded by Jake Orville and Marc S. Penn in 2009 and is headquartered in Cleveland, OH.

Viriom Ltd. operates as a biotech company which develops novel therapies for life threatening infections such as HIV and HBV. The company was founded in 2009 and is headquartered in Khimki, Russia.

Part of HealthCare Ventures LLC, Healthcare Strategic Partners, LLC is an American company that provides healthcare services.

Teal Ventures Management LLC (Teal Ventures) is a venture capital firm founded by Nikolay Savchuk, Ron Demuth, and Eddie Rodriguez in 2018. The firm Headquartered in San Diego, California.

Viriom, Inc. is a biotechnology company based in San Diego, CA. The company focuses on developing innovative therapies for infectious diseases, including HIV and COVID-19. Viriom's mission is to improve the lives of patients by providing effective and accessible treatments. Iain David Dukes has been the CEO of the company since 2019, leading the team in their efforts to advance the development of their pipeline and bring new therapies to market.

Celyn Therapeutics, Inc. develops molecule products for clinical use with a focus on targeting cancer.